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Introduction: The probability to achieve a return of spontaneous circulation (ROSC) after cardiac arrest can be
improved by optimizing circulation during cardiopulomonary resuscitation using a percutaneous left ventricular
assist device (iCPR). Inhaled nitric oxide may facilitate transpulmonary blood flow during iCPR and may therefore
improve organ perfusion and outcome.
Methods: Ventricular fibrillation was electrically induced in 20 anesthetized male pigs. Animals were left untreated
for 10 minutes before iCPR was attempted. Subjects received either 20 ppm of inhaled nitric oxide (iNO, n = 10) or
0 ppm iNO (Control, n = 10), simultaneously started with iCPR until 5 hours following ROSC. Animals were weaned
from the respirator and followed up for five days using overall performance categories (OPC) and a spatial memory
task. On day six, all animals were anesthetized again, and brains were harvested for neurohistopathologic
evaluation.
Results: All animals in both groups achieved ROSC. Administration of iNO markedly increased iCPR flow during
CPR (iNO: 1.81 ± 0.30 vs Control: 1.64 ± 0.51 L/min, p < 0.001), leading to significantly higher coronary perfusion
pressure (CPP) during the 6 minutes of CPR (25 ± 13 vs 16 ± 6 mmHg, p = 0.002). iNO-treated animals showed
significantly lower S-100 serum levels thirty minutes post ROSC (0.26 ± 0.09 vs 0.38 ± 0.15 ng/mL, p = 0.048), as
well as lower blood glucose levels 120–360 minutes following ROSC. Lower S-100 serum levels were reflected by
superior clinical outcome of iNO-treated animals as estimated with OPC (3 ± 2 vs. 5 ± 1, p = 0.036 on days 3 to 5).
Three out of ten iNO-treated, but none of the Control animals were able to successfully participate in the spatial
memory task. Neurohistopathological examination of vulnerable cerebral structures revealed a trend towards less
cerebral lesions in neocortex, archicortex, and striatum in iNO-treated animals compared to Controls.
Conclusions: In pigs resuscitated with mechanically-assisted CPR from prolonged cardiac arrest, the administration
of 20 ppm iNO during and following iCPR improved transpulmonary blood flow, leading to improved clinical
neurological outcomes.Introduction
Optimizing vital organ blood flow during cardiopulmo-
nary resuscitation (CPR) has been recognized as the key
element to increase the rate of return of spontaneous
circulation (ROSC, primary survival) and to achieve a
favorable long-term neurocognitive outcome (secondary
survival) [1].* Correspondence: mderwall@ukaachen.de
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less invasive alternative to extracorporeal CPR (eCPR)
using extracorporeal membrane oxygenation (ECMO),
as iCPR requires the cannulation of only one femoral
vessel with a 13-F sheath introducer rather than two
large-bore cannulas when using ECMO.
However, we observed that the achievable flow capacity
during ventricular fibrillation (VF) remained lower than
expected with roughly 1.36 ± 0.02 L/minute, although the
iCPR-device is technically capable of delivering a max-
imum of 2.5 L/minute. We hypothesized that this flow
restriction was primarily due to impaired left ventricular
filling, caused by depressed right-to-left transpulmonary
blood flow during VF [2].
Inhaled nitric oxide (iNO) was originally developed as
a selective pulmonary vasodilator and has been approved
since 1999 for the treatment of neonatal hypoxemia with
pulmonary hypertension [3]. It is estimated that more
than 400,000 Americans have been treated with inhaled
NO, with an excellent safety track record [4]. Additionally,
iNO has been shown to have systemic effects without
causing systemic vasodilation. For example, breathing NO
attenuates myocardial ischemia/reperfusion injury in mice
[5] and swine [6] and hepatic ischemia/reperfusion injury
in patients undergoing liver transplantation [7]. It is also
of note that iNO has been shown to improve the max-
imum flow capacity of a surgically implanted extracor-
poreal LVAD in a porcine model of hypoxemia-induced
pulmonary hypertension and right ventricular failure [8].
Based on these prior observations, we hypothesized
that iNO would increase the maximum achievable iCPR
flow capacity during resuscitation, and ameliorate the
reperfusion injury following ROSC, hence leading to
improved clinical outcomes after cardiac arrest. To
address this hypothesis, we examined the effects of
administering iNO at 20 ppm during and following
iCPR in a swine model of prolonged cardiac arrest.Fig. 1 Experimental procedure. Flowchart depicting the sequence of action
inhaled nitric oxide (iNO, n = 10) to control (n = 10). Note that no external
ET endotracheal tube, pLVAD percutaneous left ventricular assist device, VFHere, we report that iNO markedly increased the flow
capacity of iCPR and improved the neurological out-
come after cardiac arrest.
Methods
A large-animal model of cardiac arrest and CPR was
employed, as has been previously described by our group
[2, 9–12]. Twenty male domestic pigs at 4 months of
age (44.1 ± 5.8 kg) were studied. All procedures were
conducted in accordance with the principles for the care
and use of animals based on the Helsinki Declaration,
and approved by the appropriate governmental institution
(Landesamt für Natur, Umwelt und Verbraucherschutz
NRW, LANUV, Recklinghausen, Germany).
General preparation
Following induction of anesthesia, animals were intubated
and equipped with percutaneous catheters and sheath in-
troducers in femoral arteries and veins before a 5-French
pacing catheter was placed in the cephalic vein. Animals
were then equipped with a modified Impella 2.5 (iCPR-de-
vice) with a shortened angled cannula as described in [2].
All animals received two intravenous (IV) injections of
5,000 IU heparin and 1.5 g of cefuroxime to prevent blood
clotting and wound infections.
Experimental protocol
Please see Fig. 1 for a comprehensive overview of the
experimental procedure.
Following the general preparation, but before induction
of cardiac arrest, animals were randomized to either re-
ceive 20 ppm of iNO (n = 10) or nitrogen (n = 10, con-
trol), using the closed envelope method. The respective
gas was applied using a human-grade intensive care respir-
ator (Servo Ventilator 300A, Siemens, Munich, Germany).
Cardiac arrest was electrically induced, and confirmed
by the onset of VF and a rapid decrease in mean arterials taken in the experiments comparing animals treated with 20 ppm
chest compressions were applied during any stage of the experiment.
ventricular fibrillation
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was discontinued and the animal left untreated for 10
minutes. Then, iCPR-treatment was initiated by activat-
ing the previously implanted pLVAD at the maximum
possible flow. No additional chest compressions were
delivered during any phase of the experiment. To
achieve maximum flow, the Impella controller was set to
Auto-mode, in which the software automatically deter-
mines the maximum flow capacity by evaluating the
motor current to identify wall suction. Simultaneously
with the start of the pLVAD, ventilation was restarted
with an inspired oxygen fraction (FiO2) of 1.0, blended
with either 20 ppm of iNO or nitrogen, before animals
received a bolus dose of 30 μg/kg adrenaline and
Ringer’s solution at a rate of 100 mL/minute. A second
dose of adrenaline was administered 4 minutes and 30
seconds after the start of resuscitation.
After six minutes of iCPR, defibrillation was attempted
with up to two 200-J biphasic waveform shocks (M-
Series CCT; Zoll Medical Corporation, Chelmsford, MA,
USA). If an organized rhythm with an MAP >60 mmHg
persisted for 5 minutes, the animal was regarded as suc-
cessfully resuscitated. If VF was not successfully reversed,
one minute of iCPR preceded the delivery of another se-
quence of up to two shocks.
After successful resuscitation, anesthesia was con-
tinued, and animals were monitored for 6 hours. In the
iNO group, animals were ventilated with NO at 20 ppm
for up to 5 hours after ROSC. Thirty minutes following
ROSC, FiO2 was reduced to 0.3 in both groups. After
the 6-hour observation period, anesthesia was stopped
and animals weaned from the respirator as previously
described in detail [2]. Following the removal of all for-
eign materials, animals were brought to their cages and
clinically observed for up to 5 days.
Measurements
Blood pressure, heart rate, and EKG (electrocardiogram)
readings were continuously measured and digitally re-
corded. Pulmonary artery and pulmonary capillary
wedge pressure (PCWP) were measured using a hexalu-
men Swan-Ganz catheter (744HF75, Edwards Life-
sciences, Irvine, CA, USA) and a Vigilance monitor.
Cerebral oxymetry was performed and tracked using the
INVOS 5100c cerebral oxymeter and appropriate
INVOS cerebral oxymetry adult sensors (both Covidien,
Dublin, Ireland). Coronary perfusion pressure (CPP) was
calculated by subtracting the mid-diastolic right atrial
pressure from the mid-diastolic aortic pressure [13].
However, due to the non-pulsatile flow generated by the
pLVAD, CPP was calculated by subtracting the mean
right atrial pressure from mean aortic pressure during
CPR. Pulmonary vascular resistance was calculated using
equation (1) as follows:80 MPAP − PCWPð Þ
Cardiac Output
; ð1Þ
where MPAP is the mean pulmonary artery pressure and
PCWP the pulmonary capillary wedge pressure.
However, during iCPR, PCWP and cardiac output
were not available for technical reasons. PCWP was there-
fore omitted and cardiac output replaced by pLVAD flow,
resulting in equation (2). Calculating pulmonary vascular
resistance (PVR) without accounting for PCWP is fre-
quently referred to as total PVR [14]. Equation (2) is as
follows:
80 MPAPð Þ
iCPR flow
ð2Þ
The arterial oxygen and carbon dioxide tension (PaO2
and PaCO2, respectively), blood glucose levels, and lactate
levels were measured using a point-of-care blood gas
analyzer (ABL 510; Radiometer, Copenhagen, Denmark).
Blood samples were obtained at baseline (i.e., 5 minutes
before cardiac arrest) and every hour for 6 hours after
ROSC. At the same time points, serum samples to deter-
mine astroglial S-100 protein levels (to quantify neuronal
cell death) were obtained and promptly frozen to allow for
measurements at a later time using a commercially avail-
able ELISA kit (YK150, BioTrend, Cologne, Germany).
Post-arrest care
Following the resuscitation procedure and weaning from
the respirator, animals were brought to their cages and
monitored permanently by research staff. Analgesia was
provided by an intramuscular injection of 0.1 mg/kg
buprenorphine if tachypnea (>20/minutes) was observed
or an animal seemed agitated. Chow and water were
offered by gentle spoon-feeding in cases where animals
exhibited inadequate food intake. If an animal was not
able to swallow, Ringer’s solution was administered
intravenously at a rate of 10 mL/kg/h. Animals that did
not improve with this protocol and were not able to
stand up and walk within 48 hours were euthanized by
intravenous injection of a lethal dose of pentobarbital.
Euthanized animals were perfused with 4 % parafor-
maldehyde and brains carefully harvested and histopatho-
logically analyzed as described in [12]. All animals
underwent systematic necropsy of the thoracic and ab-
dominal cavities to identify injuries to the chest or thor-
acic or visceral organs.
Neurological testing
On each day post-arrest, animals were evaluated using
overall performance categories (OPC), as described in
previous studies [10, 11]. In brief, the test consists of five
items representing the degree of impairment as follows:
OPC 1, normal, no obvious neurologic damage; OPC 2,
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standing but unable to walk; OPC 3, severe disability,
animals being neither fully aware nor unconscious, but
with reaction to pain and auditory stimuli, not able to
stand or walk; OPC 4, coma; and OPC 5, death or brain
death. In animals receiving buprenorphine as part of the
post-arrest care protocol, an adequate interval (>4 hours)
was allowed to elapse before neurological testing was
performed.
In addition, animals were challenged with a visual
spatial memory task, described previously in detail in
[10]. In this test, animals are trained individually to ob-
tain food from three feeding troughs in an area sepa-
rated from their housing. Following acclimatization with
the setting, the lids of two of the containers are locked,
and the animal is expected to learn that one trough can
still be opened, and to remember this very container. To
quantify the performance, time elapsed from entering
the separated area until food is obtained is recorded.
Statistical analysis
All data are expressed as the mean ± SD unless stated
otherwise. Normal distribution of the data was con-
firmed using the Kolmogorov-Smirnov test. For group
comparisons of continuous variables, repeated measuresTable 1 Hemodynamics and blood gas data
BL PR 10
iNO n = 10 iNO n = 10
Control n = 10 Control n =
HR (bpm) iNO 89 ± 16 156 ± 47
Cont 81 ± 12 192 ± 33
MAP (mmHg) iNO 91 ± 13 89 ± 8*
Cont 94 ± 9 104 ± 14
CO (L/minute) iNO 5.0 ± 2.1 7.8 ± 2.5
Cont 5.2 ± 0.9 9.0 ± 1.8
MPAP (mmHg) iNO 14 ± 44 15 ± 4*
Cont 16 ± 4 21 ± 3
PaO2 (mmHg) iNO 139 ± 5 434 ± 92*
Cont 140 ± 6 504 ± 68
PaCO2 (mmHg) iNO 42 ± 4 40 ± 2
Cont 41 ± 3 44 ± 5
Lactate (mmol/L) iNO 1.4 ± 0.7 6.8 ± 1.4
Cont 1.4 ± 0.2 7.5 ± 1.2
Glucose (mmol/L) iNO 118 ± 16 277 ± 19
Cont 127 ± 13 294 ± 33
pH iNO 7.47 ± 0.02 7.35 ± 0.03
Cont 7.47 ± 0.04 7.30 ± 0.04
Hemodynamic and blood gas data in 20 pigs, treated either with 20 ppm of inhaled
10 (PR10), 30 (PR30), 60 (PR60), or 360 (PR360) minutes after return of spontaneous
HR heart rate, MAP mean arterial pressure, CO cardiac output, MPAP mean pulmona
dioxide tensionanalysis of variance (ANOVA) was employed followed
by the pairwise Student’s t test at given time points, ad-
justed for multiple comparisons by Bonferroni’s method
in cases where significant differences were observed.
Where appropriate, Fisher's exact test and the Mann–
Whitney U test was performed to compare categorical
variables. In all cases, p ≤0.05 was considered to indicate
statistical significance.
Results
Inhaled NO increased pLVAD flow and coronary perfusion
pressure during iCPR
Hemodynamics and blood gas results did not differ be-
tween groups before iCPR was initiated (Table 1). Group
assignment did not influence time to ROSC (iNO vs. Con-
trol: 16.5 ± 0.7 vs. minutes, p = 0.214), amount of adren-
aline given (2.2 ± 0.6 vs 2.0 ± 0.1 mg, p = 0.382) or the
number of shocks (2.6 ± 1.8 vs 3.5 ± 2.6, p = 0.387).
During iCPR, iNO treatment allowed for higher
average pump flow compared to control (1.81 ± 0.30 vs
1.64 ± 0.51 L/minute, p <0.001, see Fig. 2a), translating
into higher CPP values during the 6 minutes of iCPR be-
fore the first defibrillation was attempted (25 ± 13 vs 16 ±
6 mmHg, p = 0.002, Fig. 2b). iNO-treatment did not affect
MPAP during iCPR (12 ± 6 vs 13 ± 3 mmHg, p = 0.284).PR 30 PR 60 PR 360
iNO n = 10 iNO n = 10 iNO n = 10
10 Control n = 10 Control n = 10 Control n = 10
130 ± 56 111 ± 22 104 ± 19
164 ± 33 124 ± 24 102 ± 23
72 ± 15 70 ± 14 83 ± 6*
81 ± 12 78 ± 9 92 ± 10
4.3 ± 1.8 3.8 ± 1.5 4.6 ± 0.9
5.4 ± 1.4 3.6 ± 0.7 6.0 ± 2.2
13 ± 3 12 ± 3* 19 ± 5
16 ± 4 18 ± 4 20 ± 4
329 ± 199 136 ± 6 123 ± 18
454 ± 174 138 ± 8 135 ± 13
38 ± 3 39 ± 4 43 ± 4
39 ± 4 38 ± 4 42 ± 5
6.9 ± 1.5 5.9 ± 1.9 0.7 ± 0.2
7.3 ± 1.4 5.7 ± 1.1 1.0 ± 0.5
252 ± 25 234 ± 31 117 ± 17*
274 ± 24 251 ± 29 132 ± 12
* 7.40 ± 0.06 7.41 ± 0.06 7.46 ± 0.03
7.37 ± 0.04 7.42 ± 0.04 7.47 ± 0.04
nitric oxide (iNO; n = 10) or 0 ppm iNO (Control; n = 10) at baseline (BL) or
circulation. Results are presented as mean ± SD; *p ≤0.05 for iNO vs Control.
ry artery pressure, PaO2 arterial oxygen tension, PaCO2 arterial carbon
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mals that breathed NO than those breathing nitrogen as
soon as 3 minutes after the ROSC (17 ± 3 vs 23 ± 5
mmHg, p = 0.003). This difference in MPAP continued
until iNO was stopped at 5 hours after ROSC (Fig. 2c).
Calculated total PVR appeared to be effectively lowered,
beginning 3 minutes after the start of iNO treatment dur-
ing CPR (Fig. 2d).
NO breathing increased cerebral oxygenation without
increasing cardiac output after ROSC
Breathing NO increased cerebral oxygenation at 2 hours
after ROSC (56.5 ± 4.7 vs 47.2 ± 8.6 %, p = 0.043;
Fig. 3a). End-tidal CO2 values as a measure of the quality
of circulation trended towards higher numbers with iNO
treatment than in controls. However, this was not statis-
tically significant at any time point during CPR. Inhaled
NO did not affect cardiac output in the post-ROSC period
either (Table 1).
Inhaled NO suppressed the increase of glucose after ROSC
Blood glucose levels were not different at baseline and
up to one hour after ROSC. However, animals treated
with iNO had significantly lower blood glucose values
compared to controls, starting from 2 hours after the
start of iNO until 6 hours after the CPR procedure
(Fig. 3b).Fig. 2 Inhaled nitric oxide (iNO) impacts hemodynamics during and after card
Control (n = 10). Mean ± standard error of the mean: *p ≤0.05, comparing iN
cardiopulmonary resuscitation. a Pump flow of the intravascular cardiopulmo
c Mean pulmonary artery pressure (MPAP) measured at BL and 1, 2, 3, 4, 5, and
pulmonary vascular resistance (PVR) before (BL), during (1–6 minutes), and fol
since start of CPR. The 10-minute period of untreated ventricular fibrillation prNO breathing improved neurological outcome after
cardiac arrest
All animals in both groups achieved ROSC. However,
while five animals that breathed NO survived until day 5
post CPR, only one control animal survived until the
end of the observation period (p = 0.141, Fig. 4a). While
three iNO-treated animals were able to participate in the
spatial memory task on the first day post CPR, only one
of the controls were able to do so (Table 2). Nine control
and five iNO-treated animals had to be euthanized
prematurely due to severe neurological deficits. This
translated into significantly better score values for
iNO-treated animals in the outcome assessment with
OPC on days 3−5 post CPR (3 ± 2 vs 5 ± 1, p = 0.036 on
days 3−5; Fig. 4b).
The favorable neurological outcome was associated
with lower S-100 serum levels in iNO-treated animals,
detected as early as 30 minutes post ROSC (0.26 ± 0.09
vs 0.38 ± 0.15 ng/mL, p = 0.048; Fig. 4c).
Neurohistopathological examination of vulnerable
cerebral structures prone to ischemia-reperfusion injury
trended towards fewer cerebral lesions in iNO-treated vs
control animals euthanized on day 1 following the CPR
procedure (neocortex: 2.5 ± 1.7 vs 3.7 ± 2.3 AU, p =
0.192 ; archicortex 5.8 ± 1.5 vs 8.4 ± 4.5 AU, p = 0.142 ;
striatum 10.3 ± 1.7 vs 11.1 ± 1.2 AU, p = 0.168; Fig. 4d).
Furthermore, the single control animal surviving untiliac arrest. Comparison of animals treated with 20 ppm iNO (n = 10) or
O to Control. BL baseline (i.e., 5 minutes prior to cardiac arrest), CPR
nary resuscitation device. b Calculated coronary perfusion pressure (CPP).
6 hours after return of spontaneous circulation (ROSC). d Calculated
lowing cardiac arrest and resuscitation (7 minutes). Time indicates period
eceding CPR was omitted for clarity
Fig. 3 Inhaled nitric oxide (iNO) improves cerebral oxygenation and suppresses the increase of glucose after return of spontaneous circulation
(ROSC). Comparison of animals treated with 20 ppm iNO (n = 10) or Control (n = 10). Mean ± standard error of the mean: *p ≤0.05, comparing
iNO to Control. BL baseline (i.e., 5 minutes prior to cardiac arrest). a Cerebral oxygenation (CeSO2) was estimated using transcutaneous
spectroscopy using near-infrared light. Due to limited availability during experiments, values were estimated in 6 animals per group.
b Serum glucose levels before and after cardiac arrest and resuscitation
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than did the five iNO-treated animals that survived thus
far (neocortex: 4.6 ± 1.7 vs 7.0 AU; archicortex 10.2 ±
4.8 vs 13.0 AU; striatum 12.6 ± 6.5 vs 12.0 AU). Of note,
the neurohistopathological damage scores appeared toFig. 4 Inhaled nitric oxide (iNO) impacts the outcome after cardiac arrest. Com
Mean ± standard error of the mean: *p ≤0.05, comparing iNO to Control. ROSC
cardiac arrest), AU arbitrary units. a Number of animals that achieved R
post cardiopulmonary resuscitation (CPR). b Overall performance categories (OP
disability, animals being conscious and aware, standing but unable to walk; OPC
with reaction to pain and auditory stimuli, not able to stand or walk; OPC 4, com
minutes (1/6), 30 minutes (1/2), or 6 hours after ROSC. S-100 serum levels were e
injury. d Results from the blinded neurohistopathological evaluation in animalsrise over time in both groups, suggesting a secondary in-
jury of the cerebral tissue following the acute ischemic
insult during cardiac arrest. Systematic necropsy of the
animals revealed no macroscopic trauma to heart, valves,
or major vessels.parison of animals treated with 20 ppm iNO (n = 10) or Control (n = 10).
return of spontaneous circulation, BL baseline (i.e., 5 minutes prior to
OSC or were alive on days 1 (+1), 2 (+2), 3 (+3), 4 (+4) or 5 (+5)
C): OPC 1, normal, no obvious neurologic damage; OPC 2, moderate
3, severe disability; animals being neither fully aware nor unconscious, but
a; OPC 5, death or brain death. c S-100 protein levels measured at BL, 10
mployed as an indicator of the degree of cerebral ischemia-reperfusion
euthanized 24 hours after ROSC due to their inability to rise
Table 2 Spatial memory task
iNO Control
Alive
(n)
Testable
(n)
Time
(s)
Alive
(n)
Testable
(n)
Time
(s)
Day
−5 10 10 475 ± 233 10 10 498 ± 188
−4 10 10 338 ± 249 10 10 162 ± 251
−3 10 10 35 ± 36 10 10 141 ± 261
−2 10 10 9 ± 5 10 10 74 ± 197
−1 10 10 7 ± 2 10 10 13 ± 11
CPR
+1 9 3 406 ± 336 10 0 −
+2 5 3 402 ± 344 3 1 600 ± 0
+3 5 3 403 ± 341 1 1 600 ± 0
+4 5 3 119 ± 115 1 1 600 ± 0
+5 5 3 91 ± 126 1 1 600 ± 0
Performance of the tested animals in a spatial memory task before (Days -5 to
-1) and after (Days +1 to +5) cardiac arrest and cardiopulmonary resuscitation
(CPR). Time in seconds is provided as mean ± SD. The ability to participate in
the test was defined as the ability to stand and walk in conjunction with
physiologic searching behavior. Up to 600 seconds were allowed to complete
the test. iNO inhaled nitric oxide
Derwall et al. Critical Care  (2015) 19:328 Page 7 of 10Discussion
Here we show for the first time, that iNO enhances
transpulmonary blood flow during resuscitation with a
percutaneous axial left ventricular assist device. Im-
proved cerebral perfusion during iCPR and after ROSC
was associated with improved cerebral oxygenation and
with lower serum levels of S-100 protein. In addition we
observed a significant impact of iNO on glucose serum
levels. These beneficial hemodynamic and metabolic ef-
fects translated into improved clinical outcomes in the
first 5 days following resuscitation.
Improving hemodynamics with iNO during extracorporeal
life support and iCPR
Recently, Lovich and colleagues have shown that iNO is
capable of improving the maximum flow capacity of a
surgically implanted extracorporeal LVAD in a porcine
model of hypoxemia-induced pulmonary hypertension
and right ventricular failure [8]. In their study, 20 ppm
of iNO increased the maximum achievable pump speed,
flow, cardiac output, and left ventricular diameter. iNO
reduced pulmonary vascular resistance, right ventricular
(RV) afterload and thereby facilitated transpulmonary
blood flow. These observations are consistent with previ-
ous findings in a small randomized double-blind clinical
trial in which iNO was shown to decrease pulmonary ar-
terial pressure (PAP) and increase LVAD flow [15]. For
the first time, our study extends the concept of improving
transpulmonary blood flow with iNO to the condition of
LVAD support during CPR after prolonged cardiac arrest.Pulmonary artery pressure is known to be elevated
during conventional cardiac arrest and resuscitation,
with elevated pulmonary vascular resistance being the
primary cause [16, 17]. The intermittent high intratho-
racic pressure during external chest compressions in
concert with hypoxic pulmonary vasoconstriction may
limit right-to-left transpulmonary bloodflow during CPR.
We have previously shown that omitting chest compres-
sions during iCPR reduces pulmonary blood pressure,
but still does not solve the problem of limited transpul-
monary blood flow [2]. As iNO is a potent local vaso-
dilator, one could expect a further lowering of the mean
pulmonary artery pressure during CPR. However, this
was not the case in our investigation, as PAP was only
reduced by iNO after ROSC, but not during iCPR. In
contrast, we saw a pronounced lowering of pulmonary
vascular resistance during iCPR. As the pLVAD control-
ler increased flow as soon as the pulmonary vascular
tone was lowered, MPAP remained constant. The im-
proved pLVAD flow during iCPR then translated into
higher mean arterial pressures, which in turn led to im-
proved calculated CPP during resuscitation. This obser-
vation suggests that, when performing iCPR, MPAP may
not be a reliable indicator of effective pulmonary
vasodilation.
Regional and systemic effects of iNO during and after
cardiac arrest
Alterations in organ perfusion by iNO do not appear to
be the sole factor for influencing the clinical outcome,
because iNO did not affect serum lactate levels, a
marker for poor tissue perfusion, at any point during the
investigation. Nonetheless, we still observed a pronounced
reduction in S-100 serum protein, a proposed marker for
the degree of cerebral injury [18, 19]. Besides its beneficial
effects on iCPR performance and hemodynamics, iNO-
treated animals exhibited a significantly better clinical
outcome compared to control animals in our study. These
results corroborate findings from others, and for the first
time extend them to a large-animal model of cardiac
arrest and CPR. Minamishima and colleagues found that
in mice, breathing NO starting one hour after ROSC
markedly improved long-term neurological outcomes and
survival after 7.5 minutes of cardiac arrest, without caus-
ing systemic hypotension [20]. Neuroprotective effects of
iNO have been subsequently confirmed by several groups
that showed that inhaled NO decreased brain stroke
volume in mice, rats, and sheep [21–23]. Besides its
neuroprotective effects, several researches have reported
cardioprotective effects of iNO in mice and pigs [24–26].
The ability of iNO to reduce I/R (ischemia/reperfusion)
injury was subsequently reproduced in proof-of-principle
human studies [7, 27]. Hence, our current study provides
further support for the organoprotective properties of
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ing and after cardiac arrest.
The mechanisms through which iNO exerts its protect-
ive effects in remote organs are incompletely understood.
Inhaled NO may exert systemic effects via interaction with
circulating bone-marrow-derived cells (e.g., leukocytes) as
they transit the lungs. Alternatively, some NO, once
inhaled, may escape scavenging by hemoglobin and be
converted to relatively stable NO-metabolites (e.g., nitrite,
S-nitrosothiols) that can regenerate NO in the periphery
and directly protect neurons [28, 29]. In the current study,
we observed that iNO prevented cardiac arrest-induced
increase of blood glucose levels. Elevated glucose serum
levels seen in survivors of cardiac arrest have been identi-
fied as a predictor of adverse clinical outcomes following
resuscitation [30–33]. While glucose serves as a marker of
post-aggression metabolism and therefore, the degree of
ischemia-reperfusion injury, glucose per se may harm the
organism when reaching excessively high levels. Nonethe-
less, how iNO prevented the rise of glucose levels after
CA (Cardiac arrest) is currently unknown. Mechanisms
responsible for the protective effects of iNO in remote or-
gans remain to be determined in future studies.
In this investigation, we observed significantly lower
serum levels of S-100 protein in iNO-treated animals,
suggesting neuroprotective effects of iNO. Nonetheless,
although we saw improved clinical outcomes in iNO-
treated animals, we failed to detect histological evi-
dence that supports iNO-mediated neuroprotection.
This is likely to be due to the limited sample size and
limited number of animals surviving until day 5 of the
follow up period. It is also likely that we failed to detect
significant improvement in survival during the obser-
vation period due to the small sample size and high
mortality rate.
Limitations
There are limitations when interpreting the results of
our study: first, iCPR is a technique not frequently used
in clinical emergency medicine and may not produce the
same hemodynamic effects as chest compression CPR.
Therefore, our results may not be readily transferable to
settings in which chest compressions are used to per-
form CPR. On the other hand, use of the iCPR device
enabled standardization of the quality of CPR, thus re-
vealing the important beneficial effects of iNO in our
unique model of cardiac arrest. This study was con-
ducted in healthy, juvenile animals. Therefore, the effects
of iNO may be different in human cardiac arrest patients
with multiple comorbidities. While our current study
was not designed to examine the optimal dose or timing
of iNO administration, it is notable that the response to
iNO to prevent I/R injury is similar across multiple spe-
cies including man [7, 24, 25]. Further studies examiningthe effects of iNO during chest compression CPR, and
optimal dose and timing of administration, are therefore
warranted.
Conclusions
In summary, the current study showed that iNO aug-
ments pLVAD flow during iCPR, leading to better
hemodynamics and improved clinical outcomes in a
large-animal model of cardiac arrest. The beneficial ef-
fects of iNO may not solely depend on the improved
pLVAD flow, but may also be mediated via direct neuro-
protective effects of iNO in the post-arrest period. Cur-
rently, there is no pharmacological therapy that is
known to improve outcomes after cardiac arrest. Along
with accumulating evidence of the protective effects of
iNO after I/R injury including cardiac arrest, this first
large-animal study should provide a solid foundation to
translate this unique therapy to improve outcomes after
cardiac arrest in patients.
Key messages
 iNO facilitates transpulmonary blood flow during
iCPR
 Using 20 ppm iNO improves clinical outcomes
after CPR in pigs
 Optimal dosing and timing needs to be verified in
time-course and dose-response experiments
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